GleamWall
中文EN

INBS INTELLIGENT BIO SOLUTIONS INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1725430 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY57.2%
TTM net income YoY-11.4%
TTM EPS YoY74.6%
Revenue 3-yr CAGR27.6%
Net income 3-yr CAGR—

Margins

Gross margin50.9%
Operating margin-272.2%
Net margin-269.3%
FCF margin—
EBITDA margin-246.5%

Returns

ROE-216.1%
ROA-102.3%
ROIC (approx.)-534.9%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets46.0%
Debt / equity0.00x
Current ratio1.98x
Interest coverage-187.68x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$1.39M$1.15M$1.06M$896,774$1.11M$410,845$728,867$607,494
Cost of revenue$633,831$609,219$525,421$437,035$593,506$508,307$387,499$384,381
Gross profit$758,004$536,583$535,381$459,739$518,291$335,577$341,368$223,113
SG&A expense$2.58M$2.99M$2.46M$2.34M$2.71M$2.72M$2.41M$1.81M
Operating income-$2.68M-$3.97M-$2.95M-$2.64M-$3.00M-$3.11M-$2.56M-$2.26M
Interest expense$1,435$3,301$4,241$56,209$2,309$5,312$7,919$13,502
Net income-$2.66M-$3.91M-$2.86M-$2.68M-$2.98M-$3.09M-$2.54M-$2.25M
EBITDA-$2.39M-$3.68M-$2.66M-$2.35M-$2.70M-$2.81M-$2.26M-$1.96M
EPS (basic)-0.86—-1.80-2.82-3.49—-4.41-4.96
EPS (diluted)-0.86—-1.80-2.82-3.49—-4.41-4.96
Weighted avg. shares (diluted)3.10M—1.59M950,829854,693—577,191453,582
Balance sheet
Cash & equivalents$5.93M$3.99M$6.86M$740,371$1.66M$1.02M$2.81M$2.24M
Receivables$999,756$848,464$878,357$456,657$717,823$594,614$510,963$266,080
Inventory$478,048$418,577$597,469$590,246$628,177$635,215$683,488$701,280
Current assets$9.05M$7.10M$9.75M$12.17M$4.48M$4.14M$5.11M$4.06M
PP&E, net$278,000$294,399$312,276$321,741$271,745$251,325$546,458$537,225
Intangibles$2.60M$2.80M$3.00M$3.27M$3.47M$3.79M$3.80M$3.90M
Total assets$13.62M$11.94M$14.86M$17.65M$10.04M$8.25M$9.58M$8.68M
Current liabilities$4.58M$4.93M$4.61M$5.13M$5.06M$5.35M$4.56M$4.40M
Total liabilities$6.27M$6.65M$6.11M$6.76M$6.61M$5.44M$4.64M$4.48M
Shareholders' equity$7.58M$5.51M$8.96M$11.09M$3.62M$3.00M$5.11M$4.37M
Shares outstanding3.32M2.91M2.00M1.24M9.10M732,3276.79M4.81M
Cash flow statement
Operating cash flow-$2.75M-$3.18M-$4.33M-$1.57M-$2.85M-$2.21M-$2.76M-$2.32M
Capital expenditure—$0-$12,902$68,232$70,401———
Free cash flow—-$3.18M-$4.32M-$1.64M-$2.92M———
Investing cash flow—$0$12,902-$28,074-$70,401-$208,517-$14,385—
Financing cash flow$4.68M$311,989$10.44M$674,651$3.56M$601,997$3.32M$631,744
Depreciation & amortization$293,835$288,180$290,393$281,896$303,378$300,298$301,978$305,177
Stock-based compensation$98,368$97,429$12,204$61,575$12,000$12,000$0$12,000

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.